149 related articles for article (PubMed ID: 27445439)
41. Clinical significance of survivin and vascular endothelial growth factor mRNA detection in the peripheral whole blood of breast cancer patients.
Wang S; Xu J; Zhang Q
Neoplasma; 2016; 63(1):133-40. PubMed ID: 26639243
[TBL] [Abstract][Full Text] [Related]
42. Diagnostic Values of miR-21, miR-124, and M-CSF in Patients With Early Cervical Cancer.
Ruan F; Wang YF; Chai Y
Technol Cancer Res Treat; 2020; 19():1533033820914983. PubMed ID: 32356483
[TBL] [Abstract][Full Text] [Related]
43. Hematopoietic cytokines in the sera of patients with pancreatic cancer.
Mroczko B; Szmitkowski M; Wereszczyńska-Siemiatkowska U; Jurkowska G
Clin Chem Lab Med; 2005; 43(2):146-50. PubMed ID: 15843207
[TBL] [Abstract][Full Text] [Related]
44. Circulating macrophage colony stimulating factor as a marker of tumour progression.
McDermott RS; Deneux L; Mosseri V; Védrenne J; Clough K; Fourquet A; Rodriguez J; Cosset JM; Sastre X; Beuzeboc P; Pouillart P; Scholl SM
Eur Cytokine Netw; 2002; 13(1):121-7. PubMed ID: 11956031
[TBL] [Abstract][Full Text] [Related]
45. [The plasma levels and diagnostic utility of stem cell factor and macrophage--colony stimulating factor in endometrial cancer patients].
Lawicki S; Bedkowska E; Gacuta-Szumarska E; Czygier M; Szmitkowski M
Przegl Lek; 2007; 64(12):987-90. PubMed ID: 18595499
[TBL] [Abstract][Full Text] [Related]
46. Combined detection of plasma miR-127-3p and HE4 improves the diagnostic efficacy of breast cancer.
Lu M; Ju S; Shen X; Wang X; Jing R; Yang C; Chu H; Cong H
Cancer Biomark; 2017; 18(2):143-148. PubMed ID: 27983524
[TBL] [Abstract][Full Text] [Related]
47. The prognostic significance of LIAISON(R) CA15-3 assay in primary breast cancer.
Nisman B; Maimon O; Allweis T; Kadouri L; Maly B; Hamburger T; Peretz T
Anticancer Res; 2013 Jan; 33(1):293-9. PubMed ID: 23267160
[TBL] [Abstract][Full Text] [Related]
48. Biomarker triplet NAMPT/VEGF/HER2 as a de novo detection panel for the diagnosis and prognosis of human breast cancer.
Zhu Y; Guo M; Zhang L; Xu T; Wang L; Xu G
Oncol Rep; 2016 Jan; 35(1):454-62. PubMed ID: 26531769
[TBL] [Abstract][Full Text] [Related]
49. Serum levels of angiogenic factors in early breast cancer remain close to normal.
Duranyildiz D; Camlica H; Soydinc HO; Derin D; Yasasever V
Breast; 2009 Feb; 18(1):26-9. PubMed ID: 18996696
[TBL] [Abstract][Full Text] [Related]
50. Serum levels of macrophage colony stimulating, vascular endothelial, and placenta growth factor in relation to later clinical onset of pre-eclampsia and a small-for-gestational age birth.
Bersinger NA; Ødegård RA
Am J Reprod Immunol; 2005 Aug; 54(2):77-83. PubMed ID: 16105099
[TBL] [Abstract][Full Text] [Related]
51. Association of vascular endothelial growth factor single nucleotide polymorphisms on the prognosis of breast cancer patients.
Rani J; Rahul B; Ramesh G; Krishnamoorthy L; Shilpa C; Ramaswamy G; Deshmane V
Indian J Cancer; 2014; 51(4):512-7. PubMed ID: 26842181
[TBL] [Abstract][Full Text] [Related]
52. Plasma levels and diagnostic utility of VEGF, MMP-9, and TIMP-1 in the diagnosis of patients with breast cancer.
Ławicki S; Zajkowska M; Głażewska EK; Będkowska GE; Szmitkowski M
Onco Targets Ther; 2016; 9():911-9. PubMed ID: 26966379
[TBL] [Abstract][Full Text] [Related]
53. Comparison of serum VEGF and its soluble receptor sVEGFR1 with serum cell-free DNA in patients with breast tumor.
El Tarhouny S; Seefeld M; Fan AX; Hahn S; Holzgreve W; Zhong XY
Cytokine; 2008 Oct; 44(1):65-9. PubMed ID: 18691902
[TBL] [Abstract][Full Text] [Related]
54. HER-2 gene amplification, serum nucleosomes, CEA and CA15.3 tumor markers in breast cancer patients.
Zeiwar MM; Zaki SM; Mohammad LA; Zidan AA; El Nagar MR
Egypt J Immunol; 2007; 14(2):29-41. PubMed ID: 20306655
[TBL] [Abstract][Full Text] [Related]
55. Serum vascular endothelial growth factor in breast cancer: its relation with cancer type and estrogen receptor status.
Heer K; Kumar H; Read JR; Fox JN; Monson JR; Kerin MJ
Clin Cancer Res; 2001 Nov; 7(11):3491-4. PubMed ID: 11705867
[TBL] [Abstract][Full Text] [Related]
56. Changes in plasma vascular endothelial growth factor, angiopoietins, and their receptors following surgery for breast cancer.
Caine GJ; Stonelake PS; Lip GY; Blann AD
Cancer Lett; 2007 Apr; 248(1):131-6. PubMed ID: 16891056
[TBL] [Abstract][Full Text] [Related]
57. Plasma ALU-247, ALU-115, and cfDNA Integrity as Diagnostic and Prognostic Biomarkers for Breast Cancer.
Hussein NA; Mohamed SN; Ahmed MA
Appl Biochem Biotechnol; 2019 Mar; 187(3):1028-1045. PubMed ID: 30151636
[TBL] [Abstract][Full Text] [Related]
58. The influence of non-osteogenic factors on the expression of M-CSF and VEGF during fracture healing.
Köttstorfer J; Kaiser G; Thomas A; Gregori M; Kecht M; Domaszewski F; Sarahrudi K
Injury; 2013 Jul; 44(7):930-4. PubMed ID: 23570706
[TBL] [Abstract][Full Text] [Related]
59. Granulocyte-Colony Stimulating Factor Receptor, Tissue Factor, and VEGF-R Bound VEGF in Human Breast Cancer In Loco.
Wojtukiewicz MZ; Sierko E; Skalij P; Kamińska M; Zimnoch L; Brekken RA; Thorpe PE
Adv Clin Exp Med; 2016; 25(3):505-11. PubMed ID: 27629739
[TBL] [Abstract][Full Text] [Related]
60. Plasma vascular endothelial growth factor is useful in assessing progression of breast cancer post surgery and during adjuvant treatment.
Wu Y; Saldana L; Chillar R; Vadgama JV
Int J Oncol; 2002 Mar; 20(3):509-16. PubMed ID: 11836562
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
